SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Holdaas Hallvard)
 

Search: WFRF:(Holdaas Hallvard) > (2015-2019) > Renal function thre...

  • Mjörnstedt, Lars,1956Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery (author)

Renal function three years after early conversion from a calcineurin inhibitor to everolimus : results from a randomized trial in kidney transplantation

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • 2014-09-30
  • Frontiers Media SA,2015
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-241399
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-241399URI
  • https://doi.org/10.1111/tri.12437DOI
  • https://gup.ub.gu.se/publication/205037URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • In a 36-month, open-label, multicenter trial, 202 kidney transplant recipients were randomized at week 7 post-transplant to convert to everolimus or remain on cyclosporine: 182 were analyzed to month 36 (92 everolimus, 90 controls). Mean (SD) change in measured GFR (mGFR) from randomization to month 36 was 1.3 (14.0)ml/min with everolimus versus -1.7 (15.4)ml/min in controls (P=0.210). In patients who remained on treatment, mean mGFR improved from randomization to month 36 by 7.9 (11.5)ml/min with everolimus (n=37) but decreased by 1.4 (14.7)ml/min in controls (n=62) (P=0.001). During months 12-36, death-censored graft survival was 100%, patient survival was 98.9% and 96.7% in the everolimus and control groups, respectively, and 13.0% and 11.1% of everolimus and control patients, respectively, experienced mild biopsy-proven acute rejection (BPAR). Protocol biopsies in a limited number of on-treatment patients showed similar interstitial fibrosis progression. Donor-specific antibodies were present at month 36 in 6.3% (2/32) and 18.0% (9/50) of on-treatment everolimus and control patients with available data (P=0.281). During months 12-36, adverse events were comparable, but discontinuation was more frequent with everolimus (33.7% vs. 10.0%). Conversion from cyclosporine to everolimus at 7weeks post-transplant was associated with a significant benefit in renal function at 3years when everolimus was continued.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sorensen, Soren Schwartz (author)
  • von zur Mühlen, BengtUppsala universitet,Transplantationskirurgi(Swepub:uu)bengmuhl (author)
  • Jespersen, Bente (author)
  • Hansen, Jesper M. (author)
  • Bistrup, Claus (author)
  • Andersson, Helene (author)
  • Gustafsson, Bengt I.,1955Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery(Swepub:gu)xgusbe (author)
  • Solbu, Dag (author)
  • Holdaas, Hallvard (author)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för kirurgi (creator_code:org_t)

Related titles

  • In:Transplant International: Frontiers Media SA28:1, s. 42-510934-08741432-2277

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view